Philadelphia, PA (November 13, 2014) -- Transplanted kidneys may not function long-term if they come from donors with variants in a particular gene, according to a study that will be presented at ASN Kidney Week 2014 November 11¬-16 at the Pennsylvania Convention Center in Philadelphia, PA.
Previous research from a single center in North Carolina found that risk variants in the apolipoprotein L1 gene (APOL1) in African American deceased kidney donors were linked with shorter survival of transplanted kidneys. The APOL1 gene creates a protein that is a component of HDL, or good cholesterol. Variation in the APOL1 gene is associated with up to 40% of all kidney disease in African Americans who undergo dialysis or kidney transplantation, and APOL1 kidney risk variants are present only on the chromosomes of individuals who possess recent African ancestry.
Researchers led by Barry Freedman (Wake Forest School of Medicine) looked for the potential link between APOL1 risk variants and shorter survival of transplanted kidneys in a larger group of patients. The new multi-center study included 675 deceased donor kidney transplants from African American donors.
Results from the study confirmed that 2 APOL1 gene variants in donor kidneys were associated with more than a 2-fold increased risk of organ failure after transplantation.
"These results warrant consideration of rapidly genotyping deceased African American kidney donors for APOL1 risk variants at the time of organ recovery," said Dr. Freedman. "APOL1 genotype data should be incorporated in the organ allocation and informed-consent processes."
Study: "Apolipoprotein L1 Gene Variants in Deceased Organ Donors Are Associated with Renal Allograft Failure" (Abstract TH-OR165)
Disclosure information is available at
ASN Kidney Week 2014, the largest nephrology meeting of its kind, will provide a forum for more than 13,000 professionals to discuss the latest findings in renal research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2014 will take place November 11-16, 2014, in Philadelphia, PA.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 15,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.